Drug Type Small molecule drug |
Synonyms + [1] |
Target |
Mechanism XPO1 inhibitors(Exportin-1 protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H21ClF3N3O3 |
InChIKeyCMASLSTVVOYJQY-UHFFFAOYSA-N |
CAS Registry1076235-04-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 1 | IT | 30 Jan 2022 | |
Advanced Malignant Solid Neoplasm | Preclinical | US | 23 Feb 2016 |
NCT02667873 (ESMO2020) Manual | Phase 1 | - | (wwdwqdvbrp) = nausea (73%), vomiting (62%), fatigue (51%), decreased appetite (33%), and diarrhea (27%) nhtovrppog (ytcbhgwqjg ) View more | Positive | 17 Sep 2020 | ||
NCT02667873 (ESMO2018) Manual | Phase 1 | 35 | (qaljzjqlgg) = Not reached elyaovwdvo (pkxyjyysnb ) View more | Positive | 22 Oct 2018 |